Repligen (RGEN)

Executive Summary

Repligen is a leading bioprocessing technology company that provides critical enabling technologies for the manufacture of biologic drugs, including chromatography columns (OPUS), tangential flow filtration, fluid management, and process analytics. Its products are essential for the production of monoclonal antibodies, gene therapies, and other biologics, and the company benefits from secular tailwinds such as the growth of biologics, increasing manufacturing complexity, and outsourcing trends. Repligen has successfully transitioned from a drug developer to a pure-play bioprocess supplier, and its focus on innovation and customer partnerships has driven consistent revenue growth and margin expansion. Looking forward, Repligen is poised to capitalize on several near-term catalysts. The upcoming launch of the LentiBlock system is expected to enhance lentivirus yield for cell and gene therapy manufacturing, addressing a key bottleneck in the space. Additionally, the company continues to expand its OPUS column platform for continuous bioprocessing, which could open new markets. While the company faces some exposure to biotech sector sentiment, its strong balance sheet and strategic positioning support a favorable risk/reward profile.

Upcoming Catalysts (preview)

• Q2 2026LentiBlock System Launch for Gene Therapy Production80% success
• 2026Expansion of OPUS Column Line for Continuous Manufacturing90% success
• 2026Potential Bolt-On Acquisition to Strengthen Fluid Management Portfolio50% success